CN103328504A - 通过对流增强输送法(ced)向脑部输送选择性复制的单纯疱疹病毒载体 - Google Patents

通过对流增强输送法(ced)向脑部输送选择性复制的单纯疱疹病毒载体 Download PDF

Info

Publication number
CN103328504A
CN103328504A CN2012800060196A CN201280006019A CN103328504A CN 103328504 A CN103328504 A CN 103328504A CN 2012800060196 A CN2012800060196 A CN 2012800060196A CN 201280006019 A CN201280006019 A CN 201280006019A CN 103328504 A CN103328504 A CN 103328504A
Authority
CN
China
Prior art keywords
albumin
infusion
cells
vector
gene therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012800060196A
Other languages
English (en)
Chinese (zh)
Inventor
爱德华·怀特
史蒂文·斯特里特菲尔德·吉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renishaw PLC
Renishaw Ireland Ltd
Original Assignee
Renishaw PLC
Renishaw Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renishaw PLC, Renishaw Ireland Ltd filed Critical Renishaw PLC
Publication of CN103328504A publication Critical patent/CN103328504A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN2012800060196A 2011-01-22 2012-01-23 通过对流增强输送法(ced)向脑部输送选择性复制的单纯疱疹病毒载体 Pending CN103328504A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1101167.3A GB201101167D0 (en) 2011-01-22 2011-01-22 Convection enhanced delivery apparatus and method
GB1101167.3 2011-01-22
PCT/GB2012/000062 WO2012098367A1 (en) 2011-01-22 2012-01-23 Delivery of a selectively replicating herpes simplex viral vector to the brain by convection- enhanced delivery (ced)

Publications (1)

Publication Number Publication Date
CN103328504A true CN103328504A (zh) 2013-09-25

Family

ID=43769504

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012800060196A Pending CN103328504A (zh) 2011-01-22 2012-01-23 通过对流增强输送法(ced)向脑部输送选择性复制的单纯疱疹病毒载体

Country Status (6)

Country Link
US (1) US8901077B2 (https=)
EP (1) EP2665748A1 (https=)
JP (1) JP6010047B2 (https=)
CN (1) CN103328504A (https=)
GB (1) GB201101167D0 (https=)
WO (1) WO2012098367A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269936A (zh) * 2019-05-31 2022-04-01 阿维塔斯有限公司 向细胞群的病毒传递方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201204263D0 (en) * 2012-03-12 2012-04-25 Renishaw Plc Giloma treatment
GB201308917D0 (en) * 2013-05-17 2013-07-03 Renishaw Plc Delivery

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
DK2019683T4 (da) * 2006-04-25 2022-08-29 Univ California Indgivelse af vækstfaktorer til behandling af CNS-lidelser

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN MICHAEL ET AL: "Surface properties,more than size,limiting convective distribution of virus-sized particles and viruses in the central nervous system", 《JOURNAL OF NEUROSURGERY》 *
COSTAS G HADJIPANAYIS ET AL: "Therapeutic efficacy of a herpes simple virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery", 《MOLECULAR THERAPY》 *
RIES S J ET AL: "Oncolytic viruses for the treatment of cancer:current strategies and clinical trials", 《DRUG DISCOVERY TODAY》 *
S HARROW: "HSV1716 injection into the brain adjacent to tumor following surgical resection of high-grade glioma:safety data and long-term survival", 《GENE THERAPY》 *
WHITE E ET AL: "Evaluation and optimization of the administration of a selectively replicating herpes simple viral vector to the brain by convection-enhanced delivery", 《CANCER GENE THERAPY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269936A (zh) * 2019-05-31 2022-04-01 阿维塔斯有限公司 向细胞群的病毒传递方法

Also Published As

Publication number Publication date
US8901077B2 (en) 2014-12-02
US20130296246A1 (en) 2013-11-07
JP6010047B2 (ja) 2016-10-19
EP2665748A1 (en) 2013-11-27
GB201101167D0 (en) 2011-03-09
JP2014506563A (ja) 2014-03-17
WO2012098367A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
Hadaczek et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain
CN101180397A (zh) 用于癌症治疗基因的肿瘤选择性和高效率表达的新型hTMC启动子和载体
Hsu et al. Noninvasive and targeted gene delivery into the brain using microbubble-facilitated focused ultrasound
Yip et al. Neural stem cell biology may be well suited for improving brain tumor therapies
US7182944B2 (en) Methods of increasing distribution of nucleic acids
Goodman et al. Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies
JPH10503766A (ja) Ｈｓｖ突然変異体を用いる癌の治療
US20220168445A1 (en) Focused ultrasound for non-invasive focal gene delivery to the mammalian brain
US20020098170A1 (en) Herpes simplex virus type 1 ( HSV-1)-derived vector for selectively inhibiting maligant cells and methods for its use to treat cancer and to express desired traits in maligant and non-miligant mammalian cells
JP2002529097A (ja) アデノウィルスを介する遺伝子治療
White et al. Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery
CN103328504A (zh) 通过对流增强输送法(ced)向脑部输送选择性复制的单纯疱疹病毒载体
Chauvet et al. Selective intraarterial gene delivery into a canine meningioma
Oh et al. Efficacy of nonviral gene transfer in the canine brain
O’Leary et al. Intraparenchymal convection enhanced delivery of AAV in sheep to treat Mucopolysaccharidosis IIIC
JPH09505557A (ja) ヒト腫瘍細胞の遺伝子形質転換によるヒト腫瘍の治療
JP2007532639A (ja) 神経細胞への遺伝子送達方法
Gil et al. Utility of a herpes oncolytic virus for the detection of neural invasion by cancer
JP2001504088A (ja) 筋委縮性側索硬化症の治療方法
White et al. An evaluation of site‐specific immune responses directed against first‐generation adenoviral vectors administered by convection‐enhanced delivery
US8518391B1 (en) Monocytes as a gene delivery vector for secreted proteins to treat Alzheimer'S disease
Hampl et al. Methods for gene delivery to neural tissue
KR20200115389A (ko) 타우 단백질 집적 억제용 조성물 및 집적억제 방법
Sendra et al. Human Interleukin-10 naked DNA delivery to infarcted pig heart by catheter mediated retrograde injection in coronary sinus
CN119280424A (zh) 含Cas9/sgGDF15复合物的靶向胶质瘤的纳米胶囊及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20130925

RJ01 Rejection of invention patent application after publication